Ann Oncol 2021 Jun 8. Epub 2021 Jun 8.
Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA. Electronic address:
Background: The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-Trop-2 antibody-drug conjugate linked with the topoisomerase-inhibitor SN-38, over single-agent chemotherapy of physician's choice (TPC) in previously-treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from the ASCENT trial evaluates the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes.
Patients And Methods: Patients with mTNBC refractory to or progressing after ≥2 prior chemotherapies, with ≥1 in the metastatic setting, were randomized to receive SG (10 mg/kg intravenously days 1 and 8, every 21 days) or TPC (either capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Read More